Novartis and the Medicines for Malaria Venture (MMV) announced positive Phase 3 KALUMA results for GanLum, a ganaplacide–lumefantrine combination that cured 97.4% of participants with uncomplicated Plasmodium falciparum malaria. The 1,688‑patient, multi‑country study showed superiority versus standard therapy, and investigators pitched the new mechanism as a tool against emerging artemisinin resistance. The program advances a novel compound class discovered via high‑throughput screening and positions GanLum as a possible new frontline option if regulators concur with the trial findings.